circNFIB1 inhibits lymphangiogenesis and lymphatic metastasis via the miR-486-5p/PIK3R1/VEGF-C axis in pancreatic cancer
Top Cited Papers
Open Access
- 3 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Molecular Cancer
- Vol. 19 (1), 1-17
- https://doi.org/10.1186/s12943-020-01205-6
Abstract
Background Patients with lymph node (LN)-positive pancreatic ductal adenocarcinoma (PDAC) have extremely poor survival rates. Circular RNAs (circRNAs), a newly discovered type of endogenous noncoding RNAs, have been proposed to mediate the progression of diverse types of tumors. However, the role and underlying regulatory mechanisms of circRNAs in the LN metastasis of PDAC remain unknown. Methods Next-generation sequencing was used to identify differentially expressed circRNAs between PDAC and normal adjacent tissues. In vitro and in vivo experiments were conducted to evaluate the functional role of circNFIB1. RNA pulldown and luciferase assays were performed to examine the binding of circNFIB1 and miR-486-5p. Results In the present study, we identified that a novel circRNA (circNFIB1, hsa_circ_0086375) was downregulated in PDAC and negatively associated with LN metastasis in PDAC patients. Functionally, circNFIB1 knockdown promoted lymphangiogenesis and LN metastasis of PDAC both in vitro and in vivo. Mechanistically, circNFIB1 functioned as a sponge of miR-486-5p, and partially reversed the effect of miR-486-5p. Moreover, circNFIB1 attenuated the oncogenic effect of miR-486-5p and consequently upregulated PIK3R1 expression, which further downregulated VEGF-C expression through inhibition of the PI3K/Akt pathway, and ultimately suppressed lymphangiogenesis and LN metastasis in PDAC. Conclusions Our findings provide novel insight into the underlying mechanism of circRNA-mediated LN metastasis of PDAC and suggest that circNFIB1 may serve as a potential therapeutic target for LN metastasis in PDAC.Funding Information
- National Natural Science Foundation of China (81802530, 81871945, 81672495)
This publication has 38 references indexed in Scilit:
- Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal AdenocarcinomaAnnals of Surgery, 2019
- Regenerative medicine and cell-based approaches to restore pancreatic functionNature Reviews Gastroenterology & Hepatology, 2017
- Pancreatic cancer biology and genetics from an evolutionary perspectiveNature Reviews Cancer, 2016
- Characteristics of 10-Year Survivors of Pancreatic Ductal AdenocarcinomaJAMA Surgery, 2015
- Lymphangiogenesis and lymphatic vessel remodelling in cancerNature Reviews Cancer, 2014
- Pancreatic cancerThe Lancet, 2011
- Consensus Report of the National Cancer Institute Clinical Trials Planning Meeting on Pancreas Cancer TreatmentJournal of Clinical Oncology, 2009
- Role of Lymphangiogenesis in CancerJournal of Clinical Oncology, 2007
- Emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasisNature Reviews Cancer, 2005
- Focus on lymphangiogenesis in tumor metastasisCancer Cell, 2005